Short answer
UroGen Pharma Ltd. (URGN) filed an 8-K current report with the SEC on August 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended June 30, 2026 financial results announced.
UroGen Pharma Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 financial results announced
- Full results and management commentary contained in Exhibit 99.1
- Earnings disclosure gives investors updated operating and financial performance information
Item EX-99.1 · Exhibit EX-99.1
- ZUSDURI revenue reached $50.4M, up 73% quarter-over-quarter, signaling rapid launch adoption across 1,444 care sites
- Repeat prescribers rose to 45% from 40%, supporting improving retention and commercial durability
- Total revenue reached $72.5M versus $24.2M, while net loss narrowed to $14.4M from $49.9M
- New patent allowance could protect ZUSDURI and UGN-103 through July 2044, strengthening long-term franchise value
- Investment increased as 2026 operating expense guidance rose to $260M-$270M; UGN-103 NDA remains targeted for Q3 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UroGen Pharma Ltd. 8-K filings
Get the next URGN 8-K as it lands
Follow URGN for push alerts, or ask the research agent what this filing means.